Citation: Lj. Frewer et al., Understanding patients' preferences for treatment: the need for innovativemethodologies, QUAL HEAL C, 10, 2001, pp. I50-I54
Authors:
Bournique, B
Lambert, N
Boukaiba, R
Martinet, M
Citation: B. Bournique et al., In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine 1-carboxamide), BR J CL PH, 52(1), 2001, pp. 53-63
Authors:
Wiszniewski, W
Fondaneche, MC
Lambert, N
Masternak, K
Picard, C
Notarangelo, L
Schwartz, K
Bal, J
Reith, W
Alcaide, C
de saint Basile, G
Fischer, A
Lisowska-Grospierre, B
Citation: W. Wiszniewski et al., Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B, IMMUNOGENET, 51(4-5), 2000, pp. 261-267
Authors:
Lambert, N
Kroon, PA
Faulds, CB
Plumb, GW
McLauchlan, WR
Day, AJ
Williamson, G
Citation: N. Lambert et al., Purification of cytosolic beta-glucosidase from pig liver and its reactivity towards flavonoid glycosides, BBA-PROT ST, 1435(1-2), 1999, pp. 110-116
Authors:
Evans, PC
Lambert, N
Maloney, S
Furst, DE
Moore, JM
Nelson, JL
Citation: Pc. Evans et al., Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma, BLOOD, 93(6), 1999, pp. 2033-2037